Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
Dr. Horst Sievert,
Discussant Report: The investigators made assumptions about thromboembolic complications of elective peripheral interventions based on the published results. They developed a concept to prevent these complications with abciximab (ReoPro) and conducted a randomized multicenter trial.
This trial failed its primary combined endpoint death, amputation, re-intervention or occlusion at 30 days. There was a significant reduction of intraprocedural peripheral embolism and a significant reduction in 6 months target vessel occlusion but also a five-fold increase of severe bleeding complications.
This trial was very well designed and carefully conducted. Although the primary endpoint failed, there was some improvement with ReoPro, which was not only statistically significant but also clinically relevant. However, bleeding complications are a major cause of morbidity and mortality of peripheral interventions. Therefore the observed increase in bleeding complications is not acceptable. It is unclear whether the bleeding complications could be reduced by modified access site management. According to these results, ReoPro seems not to be indicated in elective peripheral interventions. It may be that sub-group analyses (diabetes?) will give more insights.
Reopro and peripheral arterial intervention to improve clinical outcome in patients with peripheral arterial disease (RIO-Trial).
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved